Takeda Returns Selected Assets Under Bumpy Amgen Alliance
This article was originally published in PharmAsia News
Executive Summary
Takeda is unwinding another part of its broad 2008 alliance with Amgen for the Japanese development of a portfolio of molecules, returning rights to selected assets - including trebananib - as it continues to hone its strategic focus.
You may also be interested in...
Japan Rebound For Amgen With Daiichi Biosimilars Deal
A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.
Japan Rebound For Amgen With Daiichi Biosimilars Deal
A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.